Results 71 to 80 of about 7,354 (172)

326 Modulator response of rare CFTR missense variants not approved for elexacaftor-tezacaftor-ivacaftor

, 2023
Deepak Joshi, András Rab, Eric J. Sorscher, Jeong S. Hong   +3 more
openalex   +1 more source

Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation [PDF]

, 2020
Kael Wherry, Ian O. Williamson, Richard H. Chapman, Karen M. Kuntz   +3 more
openalex   +1 more source

Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats

Frontiers in Pharmacology
Background: Ivacaftor is a modern drug used in the treatment of cystic fibrosis. It is highly lipophilic and exhibits a strong positive food effect.
Jiří Pozniak, Pavel Ryšánek, David Smrčka, Petr Kozlík, Tomáš Křížek, Jaroslava Šmardová, Anežka Nováková, Debanjan Das, Daniel Bobek, Mahak Arora, Jiří Hofmann, Tereza Doušová, Martin Šíma, Ondřej Slanař   +13 more
doaj   +1 more source

Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis

Pharmacogenomics and Personalized Medicine, 2022
Iram Haq,1,2 Maryam Almulhem,1 Simone Soars,1 David Poulton,2,3 Malcolm Brodlie1,2 1Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; 2Paediatric Respiratory Medicine, Great North ...
Haq I, Almulhem M, Soars S, Poulton D, Brodlie M   +4 more
doaj  

Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden

Therapeutic Advances in Respiratory Disease
Background: A significant decline in pulmonary exacerbation rates has been reported in CF patients homozygous for F508del treated with lumacaftor/ivacaftor. However, it is still unclear whether this reduction reflects a diminished microbiological burden.
Mahasin Al Shakirchi, Kimmo Sorjonen, Lena Hjelte, Lena Klingspor, Peter Bergman, Petrea Ericson, Marcus Svedberg, Ulrika Lindberg, Christine Hansen, Isabelle de Monestrol   +9 more
doaj   +1 more source

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Cystic Fibrosis Liver Tests in a Real-World Cohort with and Without Baseline CFLD [PDF]

, 2021
Megan E. Bowen, E. Sample, Ashley Collins, A. Singhal, Alison Brown   +4 more
openalex   +1 more source

Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Decreasing Severe Cystic Fibrosis-Related Exacerbations in Specialty Pharmacy Patients and Vulnerable Subgroups: A Retrospective, Pre-Post Study

, 2022
Christian Rhudy, Lauren Kormelink, Brittany Taylor, Sarah Hegnauer, Elizabeth Autry, Matthew Zeltner, Thom Platt   +6 more
openalex   +1 more source

Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis [PDF]

European Respiratory Review, 2013
Cystic fibrosis (CF) is caused by genetic mutations that affect the cystic fibrosis transmembrane conductance regulator (CFTR) protein. These mutations can impact the synthesis and transfer of the CFTR protein to the apical membrane of epithelial cells ...
Nico Derichs
doaj  

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation

, 2018
Kerstin Pohl, David P. Nichols, Jennifer L. Taylor‐Cousar, Milene T. Saavedra, Matthew Strand, Jerry A. Nick, Preston E. Bratcher   +6 more
openalex   +2 more sources

Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert’s syndrome [PDF]

Julia Weitzel, Matthias Welsner, Christian Taube, Manfred Ballmann, Sivagurunathan Sutharsan   +4 more
openalex   +1 more source